SIGA
SIGA Technologies, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
16.11
PEG
—
P/B
1.87
P/S
3.94
EV/EBITDA
7.91
DCF Value
$8.85
FCF Yield
13.1%
Div Yield
11.5%
Margins & Returns
Gross Margin
68.6%
Operating Margin
25.1%
Net Margin
24.6%
ROE
11.3%
ROA
10.6%
ROIC
9.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.8M | $-5.4M | $-0.08 |
| FY 2025 | $94.6M | $23.3M | $0.33 |
| Q3 2025 | $2.6M | $-6.4M | $-0.09 |
| Q2 2025 | $81.1M | $35.5M | $0.49 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.06
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.